Ultima-Retatrutide 10 mg contains retatrutide, an investigational peptide that activates three metabolic hormone receptors: GLP-1, GIP, and glucagon receptors. This unique triple-agonist activity has generated significant interest in research involving body-weight management, appetite control, fat metabolism, glucose regulation, and overall metabolic health.

How it works

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, creating a broad metabolic effect.

GLP-1 and GIP signaling can influence appetite, food intake, insulin secretion, and glucose regulation, while glucagon receptor activation is associated with energy expenditure and lipid metabolism.

This combination is being investigated for its potential to promote substantial body-weight and body-fat reduction, making retatrutide particularly interesting for research involving fat loss, body composition, and metabolic performance.

Proper Use and Dosage

The listed product contains 10 mg of retatrutide per vial.

Clinical trials have investigated retatrutide as a once-weekly subcutaneous injection, with gradual dose escalation. In a Phase 2 obesity study, weekly doses ranging from 1 mg to 12 mg were evaluated, with gradual increases used to improve tolerability.

For a 10 mg presentation:

• 1 mg = 10 administrations
• 2 mg = 5 administrations
• 2.5 mg = 4 administrations
• 5 mg = 2 administrations
• 10 mg = 1 full vial

The 10 mg presentation provides greater flexibility for protocols using repeated weekly administration. Dose escalation is generally approached gradually in clinical research rather than beginning immediately at the highest amount.

Benefits

Ultima-Retatrutide is particularly suited to applications focused on fat loss, appetite control, body composition, and metabolic health.

Key benefits and areas of interest include:

• Supports appetite-regulation research
• Promotes research into body-weight reduction
• Activates GLP-1, GIP, and glucagon receptors
• Supports glucose-metabolism research
• Investigated for increased energy expenditure
• Supports fat-metabolism research
• May support reductions in body fat
• Investigated for improvements in metabolic parameters
• Particularly interesting for body-composition research
• Convenient 10 mg presentation

Retatrutide’s triple-receptor mechanism distinguishes it from many other metabolic peptides and makes it a particularly interesting compound for next-generation fat-loss and metabolic research.

Side Effects

Clinical studies have reported effects including nausea, diarrhea, vomiting, constipation, decreased appetite, and other gastrointestinal symptoms. These effects have generally been more noticeable during periods of dose escalation.